Get the Stockscreener App
44.74
2.31%
-1.06
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $44.74, with a volume of 16.36M.
It is down -2.31% in the last 24 hours and up +9.63% over the past month.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$45.80
Open:
$45.4
24h Volume:
16.36M
Relative Volume:
0.83
Market Cap:
$198.33B
Revenue:
$50.91B
Net Income/Loss:
$18.95B
P/E Ratio:
10.50
EPS:
4.261
Net Cash Flow:
$1.92B
1W Performance:
-2.89%
1M Performance:
+9.63%
6M Performance:
-7.29%
1Y Performance:
-32.37%
1-Day Range:
$44.25
$45.50
1-Week Range:
$44.25
$47.79
52-Week Range:
$35.12
$81.44
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO vs LLY, JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
44.74 | 203.02B | 50.91B | 18.95B | 1.92B | 4.261 |
LLY
Lilly Eli Co
|
1,004.92 | 897.72B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
226.71 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
210.39 | 372.39B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
148.08 | 285.77B | 54.66B | 13.58B | 16.05B | 7.0171 |
AZN
Astrazeneca Plc
|
181.58 | 286.84B | 60.48B | 10.40B | 8.05B | 3.3297 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Initiated | Wolfe Research | Peer Perform |
| Mar-18-26 | Initiated | Bernstein | Outperform |
| Mar-10-26 | Downgrade | TD Cowen | Buy → Hold |
| Mar-03-26 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-02-26 | Downgrade | Goldman | Buy → Neutral |
| Feb-24-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-24-26 | Downgrade | Kepler | Buy → Hold |
| Feb-23-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-12-26 | Upgrade | Jefferies | Underperform → Hold |
| Jan-27-26 | Initiated | Citigroup | Neutral |
| Dec-08-25 | Downgrade | Argus | Buy → Hold |
| Oct-27-25 | Resumed | Jefferies | Underperform |
| Oct-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-29-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Sep-16-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Sep-09-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-13-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Aug-05-25 | Downgrade | UBS | Buy → Neutral |
| Jul-31-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-30-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-17-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Mar-13-25 | Upgrade | Kepler | Hold → Buy |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
Is Kailera Therapeutics a Buy After Its Sizzling IPO? - The Motley Fool
Novo Nordisk A/S stock (DK0062498333): weight-loss demand drives fresh guidance upgrade - AD HOC NEWS
Novo Nordisk A/S stock (DK0062498333): Wegovy data and earnings outlook keep GLP-1 race in focus - AD HOC NEWS
NVO Stock Quote Price and Forecast - CNN
Novo Nordisk Highlights New Wegovy Pill Data - Sahm
NVO Technical Analysis | Trend, Signals & Chart Patterns | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
Novo Nordisk A/ S stock (DK0060534915): Up 1.29% to $47 amid recovery trend - AD HOC NEWS
Novo Nordisk Oral Wegovy Data Sharpen Obesity Opportunity And Valuation Gap - Sahm
ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView
Novo Nordisk A/ S stock (DK0062498333): Wegovy data fuels 3% premarket surge - AD HOC NEWS
Amazon Pharmacy Deal Puts Novo Nordisk Access And Valuation In Focus - Sahm
Novo Nordisk A/S stock (DK0060534915): Weight-loss and diabetes leader faces new pricing pressures - AD HOC NEWS
Novo Nordisk A/S stock (DK0062498333): Q1 beats and 2026 outlook lift shares on Nasdaq Copenhagen an - AD HOC NEWS
Wegovy Pill Debut 'Fattens' Novo Nordisk's Profit Outlook - Sahm
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 15 Years - Sahm
Market news - investments.halifax.co.uk
Shares in Novo Nordisk jump after Wegovy pill sales smash forecasts - Sharecast.com
Novo Nordisk Explores New Growth In Alcohol Use Disorder And Obesity - Sahm
FDA Proposal Could Support Novo Nordisk GLP‑1 Exclusivity And Valuation - Sahm
European ADRs Jumped In US Trading, Led By Novo Nordisk - Finimize
Novo Nordisk’s Oral Ozempic And Pediatric Plans Reframe GLP-1 Opportunity - Sahm
Novo Nordisk AS (NVO) Stock Price, Trades & News - GuruFocus
Novo Nordisk (NYSE: NVO) details DKK 3.4B B-share repurchases - Stock Titan
Novo Nordisk A/S - GlobeNewswire Inc.
Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients - Sahm
NVO Stock Price, Quote & Chart | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
US-Listed European ADRs Slipped As Drugmakers Weighed On The Tape - Finimize
Novo Nordisk A/S stock (DK0062498333): Is its obesity drug dominance strong enough to sustain long-t - AD HOC NEWS
[6-K] NOVO NORDISK A S Current Report (Foreign Issuer) | NVO SEC FilingForm 6-K - Stock Titan
Novo Nordisk A/S stock (DK0062498333): Is obesity drug dominance strong enough to unlock new upside? - AD HOC NEWS
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):